Padagis LLC

Manufacturers of opioid overdose reversal drugs, including several generics firms, intend produce an additional 25m doses of their products in the US following a meeting with the White House Office of

Padagis may have to defend itself against alleged patent infringement in the US after filing the first abbreviated new drug application for a generic version of Arcutis Biotherapeutics’ Zoryve (roflu

Executive changes in the off-patent medicines industry throughout 2023 reflected a growing interest in the innovator side of the life sciences sector among leading generics and biosimilars companies.

Belgian biopharma Hyloris Pharmaceuticals SA has announced that its development partner Padagis LLC has received final approval from the US Food and Drug Administration for the first generic rival